-
公开(公告)号:US12054463B2
公开(公告)日:2024-08-06
申请号:US16646630
申请日:2018-10-30
IPC分类号: C07D239/94 , A61K51/04 , C07B59/00 , C07D401/04 , C07D401/12 , C07D403/04 , C07D471/04 , C07D487/04 , C07D491/04
CPC分类号: C07D239/94 , A61K51/0459 , C07B59/002 , C07D401/04 , C07D401/12 , C07D403/04 , C07D471/04 , C07D487/04 , C07D491/04
摘要: The present disclosure relates to radiolabeled compounds and methods of uses for diagnosis, monitoring, and treatment of various degenerative neurological disorders, neuropsychiatric disorders, brain injuries, vascular diseases, and cancers. Radiolabled compounds for imaging of microtubules or microtubules and other targets using positron-emission tomography (PET) are specifically disclosed.
-
2.
公开(公告)号:US20210059590A1
公开(公告)日:2021-03-04
申请号:US16961769
申请日:2019-01-14
发明人: Mate Istvan Milak , J. John Mann
摘要: This invention relates to the field of treatment, prevention, and identification of persons at high risk of developing major depressive disorder based upon elevated concentration of serotonin 1A receptors (i.e., elevated serotonin 1A receptor binding potential). In particular, the current invention identifies offspring of parents with major depressive disorder who are at significantly elevated risk of developing major depressive disorder before any symptoms have occurred and treats these patients prior to any symptoms and more importantly before developing major depressive disorder. The invention also relates to the identification of persons who have discontinued treatment for major depressive disorder based upon elevated concentration of serotonin 1A receptors (i.e., elevated serotonin 1A receptor binding potential).
-